GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (TSX:APS) » Definitions » Institutional Ownership

Aptose Biosciences (TSX:APS) Institutional Ownership : 0.02% (As of Mar. 15, 2025)


View and export this data going back to 1993. Start your Free Trial

What is Aptose Biosciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aptose Biosciences's institutional ownership is 0.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aptose Biosciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aptose Biosciences's Float Percentage Of Total Shares Outstanding is 95.39%.


Aptose Biosciences Institutional Ownership Historical Data

The historical data trend for Aptose Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences Institutional Ownership Chart

Aptose Biosciences Historical Data

The historical data trend for Aptose Biosciences can be seen below:

2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30
Institutional Ownership 0.05 0.05 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02

Aptose Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Aptose Biosciences Business Description

Traded in Other Exchanges
Address
251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Executives
Bernd Robert Seizinger Director
William Glenn Rice Director, Senior Officer
Erich Platzer Director
Rafael Bejar Senior Officer
Warren Whitehead Director
Gregory Kwok Lee Chow Senior Officer
Jotin Marango Senior Officer

Aptose Biosciences Headlines

No Headlines